Go offline with the Player FM app!
The new frontiers of DMT therapies
Manage episode 304070460 series 2738732
In today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech companies developing DMT therapies: Algernon, Psilera, and Pharmadrug.
In this episode, we discuss:
- DMT therapies for organ transplants, stroke patients and substance abuse disorders
- Research supporting NN-DMT’s antioxidative and anti-inflammatory effects and the receptors it targets
- Being a private company vs. public company in psychedelics
NN-DMT
5-MeO-DMT
Bioavailability
DMT transdermal patch
Sigma-1
Donepezil
Dr. Rick Strassman
Angiogenesis
Orphan Drug Designation
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh
Read the transcript here.
Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional music: Copley Beat by Blue Dot Sessions, Simplify by Little Glass Men, Pedalrider by Blue Dot Sessions, Running Waters by Jason Shaw, and Neon Drip by Blue Dot Sessions
Chapters
1. Start of episode (00:00:00)
2. Companies Overview (00:01:51)
3. Technical/Scientific Overview (00:03:22)
4. Eureka Moments (00:03:59)
5. Kidney Transplants & DMT (00:04:49)
6. IND for DMT transdermal patch (00:07:00)
7. Olson Study (00:09:16)
8. Stroke patients & Tripping (00:11:45)
9. Receptor biology (00:15:09)
10. Agonists to Serotonin receptor 2A (00:15:51)
11. Angiogenesis & Pharmadrug (00:18:32)
12. Angiogenesis VO (00:20:21)
13. Sigma-1 (00:21:53)
14. Holy Trinity (00:23:29)
15. Orphan Drug Designation (00:24:57)
16. Seeking Fundraising (00:27:52)
17. Running Public Company (00:29:42)
18. Raising capital as a public company (00:30:53)
19. Marine Sponges DMT (00:32:59)
20. Media and Natural Sources (00:34:37)
21. Biggest learning in building a company in space (00:36:03)
22. Recap of epi (00:39:52)
49 episodes
Manage episode 304070460 series 2738732
In today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech companies developing DMT therapies: Algernon, Psilera, and Pharmadrug.
In this episode, we discuss:
- DMT therapies for organ transplants, stroke patients and substance abuse disorders
- Research supporting NN-DMT’s antioxidative and anti-inflammatory effects and the receptors it targets
- Being a private company vs. public company in psychedelics
NN-DMT
5-MeO-DMT
Bioavailability
DMT transdermal patch
Sigma-1
Donepezil
Dr. Rick Strassman
Angiogenesis
Orphan Drug Designation
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh
Read the transcript here.
Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional music: Copley Beat by Blue Dot Sessions, Simplify by Little Glass Men, Pedalrider by Blue Dot Sessions, Running Waters by Jason Shaw, and Neon Drip by Blue Dot Sessions
Chapters
1. Start of episode (00:00:00)
2. Companies Overview (00:01:51)
3. Technical/Scientific Overview (00:03:22)
4. Eureka Moments (00:03:59)
5. Kidney Transplants & DMT (00:04:49)
6. IND for DMT transdermal patch (00:07:00)
7. Olson Study (00:09:16)
8. Stroke patients & Tripping (00:11:45)
9. Receptor biology (00:15:09)
10. Agonists to Serotonin receptor 2A (00:15:51)
11. Angiogenesis & Pharmadrug (00:18:32)
12. Angiogenesis VO (00:20:21)
13. Sigma-1 (00:21:53)
14. Holy Trinity (00:23:29)
15. Orphan Drug Designation (00:24:57)
16. Seeking Fundraising (00:27:52)
17. Running Public Company (00:29:42)
18. Raising capital as a public company (00:30:53)
19. Marine Sponges DMT (00:32:59)
20. Media and Natural Sources (00:34:37)
21. Biggest learning in building a company in space (00:36:03)
22. Recap of epi (00:39:52)
49 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.